Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middleincome countries

Simple item page
dc.contributor.authorMassele, Amos Y.
dc.date.accessioned2022-01-20T10:20:21Z
dc.date.available2022-01-20T10:20:21Z
dc.date.issued2020
dc.description.abstractIntroduction: There are positive aspects regarding the prescribing of fixed dose combinations (FDCs) versus prescribing the medicines separately. However, these have to be balanced against concerns including increased costs and their irrationality in some cases. Consequently, there is a need to review their value among lower- and middle-income countries (LMICs) which have the greatest prevalence of both infectious and noninfectious diseases and issues of affordability. Areas covered Review of potential advantages, disadvantages, cost-effectiveness, and availability of FDCs in high priority disease areas in LMICs and possible initiatives to enhance the prescribing of valued FDCs and limit their use where there are concerns with their value. Expert commentary FDCs are valued across LMICs. Advantages include potentially improved response rates, reduced adverse reactions, increased adherence rates, and reduced costs. Concerns include increased chances of drug:drug interactions, reduced effectiveness, potential for imprecise diagnoses and higher unjustified prices. Overall certain FDCs including those for malaria, tuberculosis, and hypertension are valued and listed in the country’s essential medicine lists, with initiatives needed to enhance their prescribing where currently low prescribing rates. Proposed initiatives include robust clinical and economic data to address the current paucity of pharmacoeconomic data. Irrational FDCs persists in some countries which are being addressed.en_US
dc.identifier.citationGodman, B., McCabe, H., D Leong, T., Mueller, D., Martin, A.P., Hoxha, I., Mwita, J.C., Rwegerera, G.M., Massele, A., Costa, J.D.O. and Do Nascimento, R.C.R.M., 2020. Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower-and middle-income countries. Expert review of pharmacoeconomics & outcomes research, 20(1), pp.1-26.en_US
dc.identifier.otherdoi.org/10.1080/14737167.2020.1734456
dc.identifier.urihttp://hdl.handle.net/123456789/868
dc.language.isoenen_US
dc.publisherExpert review of pharmacoeconomics & outcomes researchen_US
dc.subjectFixed dose combinationsen_US
dc.subjectPharmacoeconomicsen_US
dc.subjectAdherenceen_US
dc.titleFixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middleincome countriesen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Fixed dose drug combinations are they pharmacoeconomically sound Findings and implications especially for lower and middle income countries.pdf
Size:
5.81 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Journals

Total Collections: 1